Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY Putting It's Best Foot Forward

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Mar 15, 2023 7:28am

115 Views

Post# 35339097

RE:RE:RE:RE:RE:RE:RE:RE:ONCY Putting It's Best Foot Forward

Get the Word out again and again. If it's because of more results proving that we can be a player in panc cancer... why not ? It's probably part of the strategy to increase the visibility on the product and the results. GL

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?